Non-genotoxic conditioning facilitates hematopoietic stem cell gene therapy for hemophilia A using bioengineered factor VIII

Hematopoietic stem and progenitor cell (HSPC) lentiviral gene therapy is a promising strategy toward a lifelong cure for hemophilia A (HA). The primary risks associated with this approach center on the requirement for pre-transplantation conditioning necessary to make space for, and provide immune s...

Descripción completa

Detalles Bibliográficos
Autores principales: Russell, Athena L., Prince, Chengyu, Lundgren, Taran S., Knight, Kristopher A., Denning, Gabriela, Alexander, Jordan S., Zoine, Jaquelyn T., Spencer, H. Trent, Chandrakasan, Shanmuganathan, Doering, Christopher B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8181577/
https://www.ncbi.nlm.nih.gov/pubmed/34141826
http://dx.doi.org/10.1016/j.omtm.2021.04.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8181577/
https://www.ncbi.nlm.nih.gov/pubmed/34141826
http://dx.doi.org/10.1016/j.omtm.2021.04.016

Ejemplares similares